INmune Bio Inc. (INMB) financial statements (2022 and earlier)

Company profile

Business Address 1200 PROSPECT STREET
LA JOLLA, CA 92037
State of Incorp. NV
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments74,81021,9676,996186
Cash and cash equivalents74,81021,9676,996186
Receivables5911137737
Prepaid expense2,2782209816
Other undisclosed current assets4,9271,686594610
Total current assets:82,60623,9867,765849
Noncurrent Assets
Operating lease, right-of-use asset726156192
Intangible assets, net (including goodwill)16,51416,51416,51416,514
Intangible assets, net (excluding goodwill)16,51416,51416,51416,514
Other noncurrent assets99   
Total noncurrent assets:17,33916,67016,70616,514
TOTAL ASSETS:99,94540,65624,47017,363
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:3,7331,518402815
Other undisclosed accounts payable and accrued liabilities3,7331,518402815
Debt  8 
Due to related parties80342909
Other liabilities474191  
Other undisclosed current liabilities7234  
Total current liabilities:4,3591,776700824
Noncurrent Liabilities
Long-term debt and lease obligation15,162126160 
Long-term debt, excluding current maturities14,458   
Operating lease, liability704126160
Other undisclosed noncurrent liabilities(505)(126)  
Total noncurrent liabilities:15,361126160 
Total liabilities:19,7201,903861824
Stockholders' equity
Stockholders' equity attributable to parent, including:80,22538,75323,61016,540
Common stock1813119
Additional paid in capital143,92172,10544,83425,446
Accumulated other comprehensive income (loss)111(9)7
Accumulated deficit(63,715)(33,375)(21,276)(13,598)
Other undisclosed stockholders' equity attributable to parent  504,676
Total stockholders' equity:80,22538,75323,61016,540
TOTAL LIABILITIES AND EQUITY:99,94540,65624,47017,363

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues18111  
Gross profit:18111  
Operating expenses(29,334)(12,239)(7,756)(12,440)
Operating loss:(29,153)(12,228)(7,756)(12,440)
Nonoperating income (expense)(1,187)12978 
Other nonoperating income 12978 
Loss from continuing operations before income taxes:(30,340)(12,099)(7,678)(12,440)
Income tax expense(166)   
Loss before gain (loss) on sale of properties:(30,506)(12,099)(7,678)(12,440)
Other undisclosed net income166   
Net loss available to common stockholders, diluted:(30,340)(12,099)(7,678)(12,440)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(30,340)(12,099)(7,678)(12,440)
Comprehensive loss:(30,340)(12,099)(7,678)(12,440)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(10)19(15)(26)
Comprehensive loss, net of tax, attributable to parent:(30,350)(12,080)(7,693)(12,466)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: